Technical Analysis for VRTX - Vertex Pharmaceuticals Incorporated

Grade Last Price % Change Price Change
D 411.38 0.91% 3.69
VRTX closed up 0.91 percent on Monday, March 18, 2024, on 74 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
14 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Flat

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup 0.00%
Oversold Stochastic Weakness 0.00%
NR7 Range Contraction 0.91%
Oversold Stochastic Weakness 0.91%
Oversold Stochastic Weakness 0.64%
Inside Day Range Contraction -0.44%
Oversold Stochastic Weakness -0.44%
Doji - Bullish? Reversal -0.26%
Oversold Stochastic Weakness -0.26%
Stochastic Buy Signal Bullish -0.75%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakout about 15 hours ago
Rose Above 10 DMA about 15 hours ago
Rose Above Previous Day's High about 16 hours ago
10 DMA Resistance about 16 hours ago
Up 1% about 16 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Vertex Pharmaceuticals Incorporated Description

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Its products include telaprevir for the treatment of adults with genotype 1 hepatitis C virus (HCV) infection, which is marketed in the United States and Canada under the INCIVEK brand name; and ivacaftor for the treatment of cystic fibrosis that is marketed in the United States, Canada, and Europe under the KALYDECO brand name. The company, through its collaboration agreement with Janssen Pharmaceutica, N.V., also markets telaprevir in Europe and other countries in Janssen's territories under the INCIVO brand name, as well as in Japan under TELAVIC brand name. It is also developing drug candidates for the treatment of cystic fibrosis, including VX-809, which is in Phase III clinical trial and VX-661 that is in Phase II clinical trial; and drug candidates for the treatment of HCV infection, such as VX-135 (ALS-2200), which is in Phase II clinical trial and VX-222 that is in Phase II clinical trial. In addition, the company develops VX-509, which is in Phase II clinical trial for the treatment of autoimmune disease; and VX-787 that is in Phase II clinical trial for the treatment of influenza. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: S&P 500 Nasdaq 100 Autoimmune Disease Organic Compounds Chemical Compounds Infection Influenza Breakthrough Therapy Cystic Fibrosis Hepatitis C Hepatitis C Virus Treatment Of Autoimmune Disease HCV Cyclopropanes Genotype Organofluorides Treatment Of Cystic Fibrosis HCV Infection

Is VRTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 448.4
52 Week Low 297.75
Average Volume 1,251,991
200-Day Moving Average 374.63
50-Day Moving Average 424.42
20-Day Moving Average 419.27
10-Day Moving Average 411.94
Average True Range 7.97
RSI (14) 43.50
ADX 19.75
+DI 13.81
-DI 20.50
Chandelier Exit (Long, 3 ATRs) 413.09
Chandelier Exit (Short, 3 ATRs) 430.88
Upper Bollinger Bands 435.83
Lower Bollinger Band 402.71
Percent B (%b) 0.26
BandWidth 7.90
MACD Line -3.59
MACD Signal Line -2.31
MACD Histogram -1.283
Fundamentals Value
Market Cap 106.01 Billion
Num Shares 258 Million
EPS 13.87
Price-to-Earnings (P/E) Ratio 29.66
Price-to-Sales 11.05
Price-to-Book 6.20
PEG Ratio 0.57
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 420.76
Resistance 3 (R3) 421.09 418.30 419.20
Resistance 2 (R2) 418.30 415.91 418.13 418.68
Resistance 1 (R1) 414.84 414.43 416.57 414.51 418.16
Pivot Point 412.04 412.04 412.91 411.88 412.04
Support 1 (S1) 408.58 409.65 410.31 408.25 404.60
Support 2 (S2) 405.79 408.18 405.62 404.08
Support 3 (S3) 402.33 405.79 403.56
Support 4 (S4) 402.00